Table 2. SNPs significantly associated with drug response.
| Drug | Chr | RSID | -log10 (pvalue) | Most severe consequence | Host gene symbol | Host gene Ensembl ID | |
|---|---|---|---|---|---|---|---|
| 1 | Cladaribine | 7 | rs540157 | 6.52 | regulatory_region_variant | - | - |
| 2 | Cladaribine | 9 | rs72706422 | 6.14 | intergenic_variant | - | - |
| 3 | Dovitinib | 11 | rs7480726 | 6.16 | upstream_gene_variant | - | - |
| 4 | Dovitinib | 11 | rs7930221 | 6.81 | upstream_gene_variant | - | - |
| 5 | Epirubicin | 10 | rs1125411 | 7.05 | intergenic_variant | - | - |
| 6 | Epirubicin | 10 | rs7911302 | 6.97 | intergenic_variant | - | - |
| 7 | Gemcitabine | 12 | rs11043377 | 6.15 | intergenic_variant | - | - |
| 8 | Gemcitabine | 12 | rs6486806 | 7.41 | intergenic_variant | - | - |
| 9 | Hydroxyurea | 2 | rs13420950 | 6.09 | intergenic_variant | - | - |
| 10 | Oxaliplatin | 10 | rs10826348 | 7.71 | intergenic_variant | - | - |
| 11 | Oxaliplatin | 10 | rs1112962 | 6.24 | intergenic_variant | - | - |
| 12 | Paclitaxel | 2 | rs1107718 | 7.95 | intergenic_variant | - | - |
| 13 | Paclitaxel | 9 | rs4740816 | 6.23 | upstream_gene_variant | - | - |
| 14 | Tivantinib | 18 | rs11662580 | 6.52 | intergenic_variant | - | - |
| 15 | Hydroxyurea | 8 | rs13261597 | 6.01 | intron_variant | ADRA1A | ENSG00000120907 |
| 16 | Vandetanib | 7 | rs10273337 | 6.04 | intron_variant | AGAP3 | ENSG00000133612 |
| 17 | Vemurafenib | 2 | rs4664521 | 6.31 | intron_variant | CACNB4 | ENSG00000182389 |
| 18 | Vemurafenib | 2 | rs9784082 | 6.58 | intron_variant | CACNB4 | ENSG00000182389 |
| 19 | Nintedanib | 7 | rs798933 | 6.10 | intron_variant | CPED1 | ENSG00000106034 |
| 20 | Gemcitabine | 7 | rs216706 | 6.29 | intron_variant | CREB5 | ENSG00000146592 |
| 21 | Vinorelbine | 8 | rs1478275 | 6.04 | intron_variant | CSMD1 | ENSG00000183117 |
| 22 | Vemurafenib | 6 | rs12191002 | 6.07 | intron_variant | GMDS-DT | ENSG00000250903 |
| 23 | Gemcitabine | 10 | rs17142881 | 7.10 | intron_variant | ITIH5 | ENSG00000123243 |
| 24 | Vinblastine | 16 | rs1693956 | 6.12 | intron_variant | LINC01081 | ENSG00000268754 |
| 25 | Oxaliplatin | 10 | rs11006706 | 8.91 | intron_variant | MKX-AS1 | ENSG00000230500 |
| 26 | Carboplatin | 20 | rs6010746 | 6.27 | intron_variant | MRGBP | ENSG00000101189 |
| 27 | Arsenic trioxide | 16 | rs11641233 | 6.05 | 3_prime_UTR_variant | NFAT5 | ENSG00000102908 |
| 28 | Erlotinib | 16 | rs11639947 | 8.39 | intron_variant | NFAT5 | ENSG00000102908 |
| 29 | Erlotinib | 16 | rs11641233 | 8.16 | 3_prime_UTR_variant | NFAT5 | ENSG00000102908 |
| 30 | Erlotinib | 16 | rs12232410 | 9.10 | 3_prime_UTR_variant | NFAT5 | ENSG00000102908 |
| 31 | Erlotinib | 16 | rs12447326 | 9.17 | intron_variant | NFAT5 | ENSG00000102908 |
| 32 | Erlotinib | 16 | rs2361838 | 7.91 | intron_variant | NFAT5 | ENSG00000102908 |
| 33 | Erlotinib | 16 | rs58643880 | 8.12 | 3_prime_UTR_variant | NFAT5 | ENSG00000102908 |
| 34 | Paclitaxel + Epirubicin | 16 | rs11639947 | 6.18 | intron_variant | NFAT5 | ENSG00000102908 |
| 35 | Trametinib | 16 | rs11639947 | 8.11 | intron_variant | NFAT5 | ENSG00000102908 |
| 36 | Trametinib | 16 | rs11641233 | 6.14 | 3_prime_UTR_variant | NFAT5 | ENSG00000102908 |
| 37 | Trametinib | 16 | rs12447326 | 6.08 | intron_variant | NFAT5 | ENSG00000102908 |
| 38 | Trametinib | 16 | rs2361838 | 6.70 | intron_variant | NFAT5 | ENSG00000102908 |
| 39 | Trametinib | 16 | rs58643880 | 7.08 | 3_prime_UTR_variant | NFAT5 | ENSG00000102908 |
| 40 | Arsenic trioxide | 16 | rs1437135 | 6.04 | intron_variant | NQO1 | ENSG00000181019 |
| 41 | Erlotinib | 16 | rs1437135 | 8.31 | intron_variant | NQO1 | ENSG00000181019 |
| 42 | Erlotinib | 16 | rs1800566 | 8.69 | missense_variant | NQO1 | ENSG00000181019 |
| 43 | Paclitaxel + Epirubicin | 16 | rs1800566 | 6.15 | missense_variant | NQO1 | ENSG00000181019 |
| 44 | Trametinib | 16 | rs1437135 | 6.64 | intron_variant | NQO1 | ENSG00000181019 |
| 45 | Trametinib | 16 | rs1800566 | 8.07 | missense_variant | NQO1 | ENSG00000181019 |
| 46 | Erlotinib | 8 | rs2444306 | 6.58 | intron_variant | OXR1 | ENSG00000164830 |
| 47 | Temozolomide | 3 | rs4470517 | 6.15 | intron_variant | RYK | ENSG00000163785 |
| 48 | Temozolomide | 3 | rs4854617 | 6.47 | intron_variant | RYK | ENSG00000163785 |
| 49 | Fluoro-deoxyuridine | 4 | rs9994654 | 7.20 | intron_variant | SLC9B1 | ENSG00000164037 |
| 50 | Fluoro-deoxyuridine | 4 | rs10516497 | 6.63 | intron_variant | SLC9B2 | ENSG00000164038 |
| 51 | Docetaxel | 5 | rs2304035 | 6.76 | missense_variant | SLIT3 | ENSG00000184347 |
SNPs associated with the multivariate response for each drug at the genome-wide suggestive significance level or higher from the genome-wide association mapping using MAGWAS. The results are sorted by the host gene and drug. Chr: Chromosome, The most severe consequence obtained from Ensembl VEP (Ensembl release 97 –July 2019).